Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

About Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FPRX
  • CUSIP: N/A
  • Web: www.fiveprime.com
Capitalization:
  • Market Cap: $831.61 million
  • Outstanding Shares: 27,897,000
Average Prices:
  • 50 Day Moving Avg: $32.18
  • 200 Day Moving Avg: $43.98
  • 52 Week Range: $28.17 - $60.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.32
  • P/E Growth: 0.11
Sales & Book Value:
  • Annual Revenue: $34.31 million
  • Price / Sales: 24.24
  • Book Value: $12.80 per share
  • Price / Book: 2.33
Profitability:
  • EBIDTA: ($111,050,000.00)
  • Net Margins: 64.94%
  • Return on Equity: 59.23%
  • Return on Assets: 49.60%
Debt:
  • Current Ratio: 11.60%
  • Quick Ratio: 11.60%
Misc:
  • Average Volume: 438,765 shs.
  • Beta: 4.36
  • Short Ratio: 5.89
 

Frequently Asked Questions for Five Prime Therapeutics (NASDAQ:FPRX)

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics Inc (NASDAQ:FPRX) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($1.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.96) by $0.25. The company had revenue of $10.13 million for the quarter, compared to the consensus estimate of $6.05 million. Five Prime Therapeutics had a net margin of 64.94% and a return on equity of 59.23%. The firm's revenue for the quarter was up 55.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.49) EPS. View Five Prime Therapeutics' Earnings History.

Where is Five Prime Therapeutics' stock going? Where will Five Prime Therapeutics' stock price be in 2017?

7 analysts have issued 12 month price objectives for Five Prime Therapeutics' stock. Their predictions range from $54.00 to $94.00. On average, they expect Five Prime Therapeutics' stock price to reach $65.20 in the next year. View Analyst Ratings for Five Prime Therapeutics.

What are analysts saying about Five Prime Therapeutics stock?

Here are some recent quotes from research analysts about Five Prime Therapeutics stock:

  • 1. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)
  • 2. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (5/2/2017)
  • 3. Cowen and Company analysts commented, "We believe Five Prime has amongst the leading IO drug discovery platforms in the industry. The BMS partnership provides validation. Multiple clinical readouts in 2017 provide catalysts to drive value generation. Lead asset Cabira has significant potential in solid tumors, we expect FPA144 to succeed in FGFR2b+ gastric cancer (2019), and we see high POS for Cabira in PVNS. Initiating at Outperform." (3/24/2017)
  • 4. Instinet analysts commented, "We are initiating on Five Prime Therapeutics (FPRX) with a Buy rating and a $94, 12-month target price. We recommend owning FPRX shares ahead of potentially transformational mid-2017 readouts. We anticipate 2017 data from cabiralizumab and key competitors will further de-risk cabiralizumab's anti-CSF1R mechanism in immuno-oncology, define pivotal clinical paths, establish initial market opportunities, and differentiate its safety versus competitors." (3/1/2017)

Are investors shorting Five Prime Therapeutics?

Five Prime Therapeutics saw a increase in short interest in April. As of April 28th, there was short interest totalling 2,275,852 shares, an increase of 1.3% from the April 13th total of 2,246,085 shares. Based on an average daily trading volume, of 337,919 shares, the short-interest ratio is presently 6.7 days.

Who are some of Five Prime Therapeutics' key competitors?

Who owns Five Prime Therapeutics stock?

Five Prime Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.79%), Wellington Management Group LLP (8.06%), Vanguard Group Inc. (6.02%), State Street Corp (4.48%), Dimensional Fund Advisors LP (3.39%) and BB Biotech AG (2.64%). Company insiders that own Five Prime Therapeutics stock include Adage Capital Partners Gp Llc, Francis Willard Sarena, Franklin M Berger, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

Who sold Five Prime Therapeutics stock? Who is selling Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Vanguard Group Inc., OppenheimerFunds Inc., Eventide Asset Management LLC, Wellington Management Group LLP, Russell Investments Group Ltd., Schwab Charles Investment Management Inc. and Capital Fund Management S.A.. Company insiders that have sold Five Prime Therapeutics stock in the last year include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Insider Buying and Selling for Five Prime Therapeutics.

Who bought Five Prime Therapeutics stock? Who is buying Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including BB Biotech AG, Renaissance Technologies LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., State Street Corp, Goldman Sachs Group Inc., Dimensional Fund Advisors LP and FMR LLC. View Insider Buying and Selling for Five Prime Therapeutics.

How do I buy Five Prime Therapeutics stock?

Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Five Prime Therapeutics stock cost?

One share of Five Prime Therapeutics stock can currently be purchased for approximately $29.81.

Analyst Ratings

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $65.20 (118.72% upside)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Jefferies Group LLCReiterated RatingBuy$55.00N/AView Rating Details
3/24/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$94.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
11/7/2016Credit Suisse Group AGReiterated RatingBuy$54.00N/AView Rating Details
10/25/2016Citigroup IncInitiated CoverageBuy$65.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00N/AView Rating Details
5/19/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$48.00N/AView Rating Details
4/12/2016BMO Capital MarketsInitiated CoverageMarket Perform$50.00N/AView Rating Details
12/4/2015Wells Fargo & CoReiterated RatingOutperformN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)
Earnings by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Earnings History by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.96)($1.21)$6.05 million$10.13 millionViewListenView Earnings Details
2/23/2017Q4 2016($0.57)($0.73)$7.09 million$8.30 millionViewN/AView Earnings Details
11/3/2016Q3($0.51)($0.72)$7.50 million$6.70 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.46)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.40)($0.55)$5.39 million$4.65 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.40)($0.33)$5.22 million$6.06 millionViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)$5.39 million$4.98 millionViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)$1.52 million$3.79 millionViewListenView Earnings Details
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
2017 EPS Consensus Estimate: ($4.21)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.97)($0.97)($0.97)
Q2 20171($1.03)($1.03)($1.03)
Q3 20171($1.08)($1.08)($1.08)
Q4 20171($1.13)($1.13)($1.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 93.38%
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/1/2017William R RingoDirectorSell500$46.73$23,365.00View SEC Filing  
2/1/2017William R RingoDirectorSell500$46.17$23,085.00View SEC Filing  
1/18/2017Francis Willard SarenaInsiderSell3,636$47.39$172,310.04View SEC Filing  
1/3/2017William R RingoDirectorSell500$51.07$25,535.00View SEC Filing  
12/23/2016Lewis T WilliamsCEOSell30,000$50.50$1,515,000.00View SEC Filing  
12/1/2016William R RingoDirectorSell500$57.72$28,860.00View SEC Filing  
11/28/2016Francis Willard SarenaInsiderSell1,710$60.14$102,839.40View SEC Filing  
11/25/2016Francis Willard SarenaInsiderSell34,654$60.38$2,092,408.52View SEC Filing  
11/9/2016Peder JensenDirectorSell8,130$55.30$449,589.00View SEC Filing  
11/1/2016William R RingoDirectorSell500$48.67$24,335.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$52.00$26,000.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$44.20$22,100.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$50.77$25,385.00View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.50View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Five Prime Therapeutics (NASDAQ:FPRX)
Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Five Prime Therapeutics, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 4:56 PM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Short Interest Update
www.americanbankingnews.com - May 21 at 11:14 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) ASCO abstract published on phase I/II dose escalation and expansion study of cabiralizumab
www.streetinsider.com - May 18 at 10:06 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) Names Garry Nicholson to Board of Directors - StreetInsider.com
www.streetinsider.com - May 17 at 5:17 PM
finance.yahoo.com logoFive Prime Welcomes Garry Nicholson to Board of Directors
finance.yahoo.com - May 15 at 4:56 PM
seekingalpha.com logoFive Prime Therapeutics At An Attractive Entry Level
seekingalpha.com - May 12 at 10:51 PM
finance.yahoo.com logoETFs with exposure to Five Prime Therapeutics, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:55 PM
finance.yahoo.com logoFive Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 5:09 PM
americanbankingnews.com logoJefferies Group Comments on Five Prime Therapeutics Inc's FY2021 Earnings (FPRX)
www.americanbankingnews.com - May 8 at 12:30 PM
globenewswire.com logoFive Prime Announces First Quarter 2017 Results and Provides ... - GlobeNewswire (press release)
globenewswire.com - May 5 at 10:29 PM
finance.yahoo.com logoFive Prime Therapeutics posts 1Q loss
finance.yahoo.com - May 5 at 5:28 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for Five Prime Therapeutics Inc (FPRX)
www.americanbankingnews.com - May 5 at 11:58 AM
seekingalpha.com logoFive Prime Therapeutics' (FPRX) CEO Rusty Williams on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 3:29 AM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Releases Quarterly Earnings Results, Misses Estimates By $0.25 EPS
www.americanbankingnews.com - May 5 at 12:08 AM
finance.yahoo.com logoFive Prime Announces First Quarter 2017 Results and Provides Business Update
finance.yahoo.com - May 4 at 5:27 PM
finance.yahoo.com logoInvestor Network: Five Prime Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 12:19 PM
americanbankingnews.com logoFive Prime Therapeutics (FPRX) Receives Coverage Optimism Score of 0.33
www.americanbankingnews.com - May 3 at 8:52 PM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 3 at 1:11 AM
americanbankingnews.com logo Analysts Expect Five Prime Therapeutics Inc (FPRX) Will Announce Earnings of -$1.01 Per Share
www.americanbankingnews.com - May 2 at 10:00 AM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 1 at 9:18 PM
americanbankingnews.com logoFavorable Press Coverage Extremely Likely to Impact Five Prime Therapeutics (FPRX) Share Price
www.americanbankingnews.com - April 30 at 10:51 AM
americanbankingnews.com logoFive Prime Therapeutics (FPRX) Receiving Favorable Press Coverage, Study Finds
www.americanbankingnews.com - April 27 at 10:30 AM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 26 at 10:46 PM
americanbankingnews.com logoFive Prime Therapeutics (FPRX) Earns Daily News Impact Score of 0.36
www.americanbankingnews.com - April 24 at 4:16 PM
americanbankingnews.com logoFive Prime Therapeutics (FPRX) Getting Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 21 at 8:22 PM
nasdaq.com logoFive Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4 - Nasdaq
www.nasdaq.com - April 21 at 5:18 PM
finance.yahoo.com logoFive Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4
finance.yahoo.com - April 20 at 5:23 PM
finance.yahoo.com logoFive Prime to Present Clinical Data at 2017 ASCO Annual Meeting
finance.yahoo.com - April 20 at 5:23 PM
americanbankingnews.com logoPositive News Coverage Extremely Likely to Effect Five Prime Therapeutics (FPRX) Stock Price
www.americanbankingnews.com - April 16 at 10:17 AM
americanbankingnews.com logoPositive Media Coverage Extremely Likely to Effect Five Prime Therapeutics (FPRX) Stock Price
www.americanbankingnews.com - April 13 at 8:54 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) Reports Complete Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab
www.streetinsider.com - April 11 at 5:04 PM
nasdaq.com logoFive Prime Therapeutics Announces Completion of Enrollment for the Phase 2 ...
www.nasdaq.com - April 11 at 12:26 PM
americanbankingnews.com logo-$1.01 EPS Expected for Five Prime Therapeutics Inc (FPRX) This Quarter
www.americanbankingnews.com - April 11 at 12:21 AM
reuters.com logoBRIEF-Five Prime Therapeutics announces completion of enrollment for the phase 2 of the ongoing trial of Cabiralizumab
www.reuters.com - April 10 at 5:01 PM
finance.yahoo.com logoFive Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)
finance.yahoo.com - April 10 at 5:01 PM
seekingalpha.com logoFive Prime Therapeutics completes enrollment for trial
seekingalpha.com - April 10 at 4:25 PM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 4 at 4:18 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at AACR - StreetInsider.com
www.streetinsider.com - April 4 at 3:33 AM
reuters.com logoBRIEF-Five Prime Therapeutics presents preclinical research data on csf-1r and pd-1 blockade
www.reuters.com - April 3 at 10:31 PM
finance.yahoo.com logoFive Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting
finance.yahoo.com - April 3 at 5:30 PM
finance.yahoo.com logoFive Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting
finance.yahoo.com - April 3 at 9:40 AM
finance.yahoo.com logoFive Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR Annual Meeting - Yahoo Finance
finance.yahoo.com - April 2 at 10:11 PM
reuters.com logoBRIEF-Five Prime Therapeutics Inc CEO's 2016 total compensation was $8.1 mln
www.reuters.com - March 31 at 5:22 PM
seekingalpha.com logoFive Prime Therapeutics: Initiating Coverage With A Buy Rating And A $56 Price Target
seekingalpha.com - March 30 at 10:43 PM
seekingalpha.com logoFive Prime At Lows With Looming Catalysts
seekingalpha.com - March 27 at 4:58 PM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Lowered to D+ at TheStreet
www.americanbankingnews.com - March 24 at 9:40 PM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Research Coverage Started at Cowen and Company
www.americanbankingnews.com - March 24 at 3:01 PM
finance.yahoo.com logo4:05 pm Five Prime Therapeutics names Helen Collins, M.D., as Senior Vice President and Chief Medical Officer
finance.yahoo.com - March 20 at 7:24 PM
finance.yahoo.com logoFive Prime Therapeutics Announces Executive Changes
finance.yahoo.com - March 20 at 7:24 PM
biz.yahoo.com logoFIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 20 at 7:24 PM

Social

Chart

Five Prime Therapeutics (FPRX) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff